Revised classification of acute myeloid leukemia

Leukemia

Volumn 10, Issue 11, 1996, Pages 1826-1831

  Head, D R ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

AML; Classification; FAB; MDS; Model

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER INCIDENCE; CHILD; CHILDHOOD LEUKEMIA; DISEASE COURSE; DYSPLASIA; FANCONI ANEMIA; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC DAMAGE; GENETIC MARKER; HEMATOPOIESIS; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0029798607     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Copplestone JA, Prentice AG. Acute myeloblastic leukaemia in the elderly. Leuk Res 1988; 12: 617-625.
2. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates and of incidence of complete remission. Cancer Treat Rep 1985; 69: 5-11.
3. Selvin S, Levin LI, Merrill DW, Winkelstein W Jr. Selected epidemiologic observations of cell-specific leukemia mortality in the United States, 1969-1977. Am J Epidemiol 1983; 117: 140-152.
4. Champlin RE, Gajewski JL, Golde DW. Treatment of acute myelogenous leukemia in the elderly. Semin Oncol 1989; 16: 51-56.
5. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451-458.
6. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the diagnosis of acute myeloid leukemia. Ann Intern Med 1985; 103: 620-625.
7. Koeffler HP. Myelodysplastic syndromes (preleukemia). Semin Hematol 1986; 23: 284-299.
8. Layton DM, Mufti GJ. Myelodysplastic syndromes: their history, evolution, and relation to acute myeloid leukaemia. Blutt 1986; 53: 423-436.
9. Tomonaga M, Tomonaga Y, Kusano M, Ichimaru M. Sequential karyotypic evolutions and bone marrow aplasia preceding acute myelomonocytic transformation from myelodysplastic syndrome. Br J Haematol 1984; 58: 53-60.
10. Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 1984; 63: 1318-1323.
11. Aul C, Gatterman N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 358-367.
12. Hasle H. Myelodysplastic syndromes in childhood - classification, epidemiology, and treatment. Leuk Lymphoma 1994; 13: 11-26.
13. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
14. Foucar K, Langdon RM II, Armitage JO, Olson DB, Carroll TJ Jr. Myelodysplastic syndromes, a clinical and pathologic analysis of 109 cases. Cancer 1985; 56: 553-561.
15. Levine EG, Bloomfield CD. Secondary myelodysplastic syndromes and leukaemias. Clin Haematol 1986; 15: 1037-1080.
16. Tuncer MA, Pagliuca A, Hicsonmez G, Yetgin S, Ozsoylu S, Mufti GJ. Primary myelodysplastic syndrome in children: the clinical experience in 33 cases. Br J Haematol 1992; 82: 347-353.
17. Creutzig U, Cantu-Rajnoldi A, Ritter J, Romitti L, Odenwald E, Conter V, Riehm H, Masera G. Myelodysplastic syndromes in childhood: report of 21 patients from Italy and West Germany. Am J Pediatr Hematol/Oncol 1987; 9: 324-330.
18. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients: a review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet 1991; 51: 1-12.
19. Magenis RE, Yoshitomi M, Smith L, Bagby GC Jr. Cytogenetic studies on marrow cells from patients with the preleukemic syndrome. In: Bagby GC Jr (ed). The Preleukemic Syndrome (Hemopoietic Dysplasia). CRC Press: Boca Raton, FL, 1985, pp 103-126.
20. Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985; 60: 507-516.
21. Heim S, Mittelman F. Acute nonlymphocytic leukemia, and myelodysplastic syndromes. Cancer Cytogenetics. Alan R Liss: New York, NY, 1989, pp 65-140.
22. Henderson SH. Acute leukemia: general considerations. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA (eds). Hematology, 4th edn. McGraw-Hill: New York, 1990, p 237.
23. Stevens RG. Age and risk of acute leukemia. J Natl Cancer Inst 1986; 76: 845-848.
24. Forty-five Years of Cancer Incidence in Connecticut, 1935-79. National Cancer Institute Monograph 70. US Government Printing Office: Washington, DC, 1986, pp 84-85.
25. Surveillance and Mortality Data 1973 to 1977. US Department of Health and Human Services: Washington, DC.
26. Statistical Abstract of the United States: 1991 (11th edn). Washington, DC: US Bureau of the Census, 1991.
27. Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1984; 11: 265-274.
28. Whang-Peng J, Knutsen T. The role of cytogenetics in the characterization of acute leukemia. In: Stass SA (ed). The Acute Leukemias: Biologic, Diagnostic, and Therapeutic Determinants. Marcel Dekker: New York, 1987, pp 153-201.
29. Rowley JD, Alimena G, Garson OM, Hagemeijer A, Mitelman F, Prigogina EL. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood 1982; 59: 1013-1022.
30. Carroll A, Civin C, Schneider N, Dahl G, Pappo A, Bowman P, Emami A, Gross S, Alvarado C, Phillips C, Krischer J, Crist W, Head D, Gresik M, Ravindranath Y, Weinstein H. The t(1;22)(p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood 1991; 78: 748-752.
31. Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic and cytogenetic working classification of the primary and therapy-related myelodysplastic disorders. Cancer Genet Cytogenet 1988; 32: 1-10.
32. Foucar K, McKenna RW, Bloomfield CD, Bowers TK, Brunning RD. Therapy related leukemia: a panmyelosis. Cancer 1979; 43: 1285-1296.
33. Kalwinsky DK, Raimondi SC, Schell MJ, Mirro J, Santana VM, Behm F, Dahl GV, Williams D. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 1990; 8: 75-83.
34. Head DR, Savage RA, Cerezo L, Craven CM, Bickers JN, Hartsock R, Hosty TA, Saiki JH, Wilson HE, Morrison FS, Coltman CA, Hutton JJ. Reproducibility of the French-American-British classification of acute leukemia, the Southwest Oncology Group experience. Am J Hematol 1985; 18: 47-57.
35. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG. Report of the National Cancer Institute-sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
36. Von Boros J, Karenyi A. Über einem fall von akuter megakaryoblastenleukämie, zugleich einige bemerkungen zum problem der akuten leukämie. Z Klin Med 1931; 118: 697-718.
37. Swirsky DM, de Bastos M, Parish SE, Rees JKH, Hayhoe FGJ. Features affecting outcome during remission induction of acute myeloid leukemia in 619 adult patients. Br J Haematol 1986; 64: 435-453.
38. Mertelsmann R, Thaler HT, To L, Gee TS, McKenzie S, Schauer P, Friedman A, Arlin Z, Cirrincione C, Clarkson B. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphocytic leukemia. Blood 1980; 56: 773-781.
39. Morrison FS, Kopecky KJ, Head DR, Athens JW, Balcerzak SP, Gumbart C, Dabich L, Costanzi JJ, Coltman CA, Saiki JH, Hussein KK, Fabian CJ, Appelbaum FR. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia - results of a Southwest Oncology Group study of rubidazone vs adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. Leukemia 1992; 6: 708-714.
40. Chan GCF, Wang W, Raimondi S, Behm F, Krance R, Head D. Distinction of acute myeloid leukemia (AML) with low blast count from pediatric myelodysplastic syndrome (MDS) is clinically important. Blood 1994; 84: 315a.
41. Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S, AML-associated cytogenetic abnormalities (inv(16), del(16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 1992; 6: 43-48.
42. Raimondi SC, Kalwinsky DK, Hayashi Y, Behm FG, Mirro J Jr, Williams DL. Cytogenetics of childhood acute non-lymphocytic leukemia. Cancer Genet Cytogenet 1989; 40: 13-27.
43. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Drabkin HA, Willman C, Theil KS, Civin CI, Erickson P. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993; 81: 2860-2865.
44. Shurtleff SA, Meyers S, Hiebert SW, Raimondi SC, Head DR, Willman CL, Wolman S, Carroll AJ, Behm F, Hulshof MG, Motroni TA, Okuda T, Liu P, Collins FS, Downing JR. Heterogeneity in CBFβ/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 1995; 85: 3695-3703.
45. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res 1987; 11: 119-133.
46. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263-270.
47. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW. Associations between morphology, karyotype, and clinical fetures in myeloid leukemias. Hum Pathol 1987; 18: 211-225.
48. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. New Engl J Med 1987; 317: 468-473.
49. Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 1987; 66: 445-450.
50. Jinnai I, Tomonaga M, Kuriyama K, Matsuo T, Nonaka H, Amenomori T, Yoshida Y, Kusano M, Tagawa M, Ichimaru M. Dysmegakaryocytopoiesis in acute leukaemias: its predominance in myelomonocytic (M4) leukaemia and implication for poor response to chemotherapy. Br J Haematol 1987; 66: 467-472.
51. Foucar K, Vaughan WP, Armitage JO, Patil S, Dick F, Karp JE. Postleukemic dysmyelopoiesis. Am J Hematol 1983; 15: 321-334.
52. Willman CL, Kopecky KJ, Weick J, Appelbaum F, Head DR, Grever M, Elias L, Balcerzak SP, Mills GM, Hynes HE. Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside. Proc ASCO 1992; 11: 262a.
53. Holmes JA, West RR, Whittaker JA, Jacobs A. Correlation of MDR status with clinical outcome in patients with acute myeloblastic leukaemia. Br J Haematol 1991; 77: 130-131.
54. Radich JP, Kopecky K, Willman CL, Weick J, Head D, Appelbaum F, Collins SJ. N-ras mutations in adult de novo acute myelogenous leukemia: incidence and clinical significance. Blood 1990; 76: 801-807.
55. Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O, Isaac G, McCormick F, Koeffler HP. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590-599.
56. Van Kamp H, de Pijper C, Verlaan-de Vries M, Bos JL, Leeksma CHW, Kerkhofs H, Willemze R, Fibbe WE, Landegent JE. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 1992; 79: 1266-1270.
57. Yamamoto K, Hirosawa S, Sakamaki H, Aoki N. Frequent rearrangements of retinoic acid receptor alpha gene and MyI gene, and rare mutations of RAS and FMS genes in acute promyelocytic leukemia. Am J Hematol 1992; 40: 252-258.
58. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic syndrome, leukemic, and normal subjects. Proc Natl Acad Sci USA 1990; 87: 1377-1380.
59. Second MIC Cooperative Study Group. Morphologic, immunologie, and cytogenetic (MIC) working classification of the acute myeloid leukemias. Cancer Genet Cytogenet 1988; 30: 1-15.
60. Tricot G, Mecucci C, Van Den Berghe H. Evolution of the myelodysplastic syndromes. Br J Haematol 1986; 63: 609-614.
61. Copplestone JA, Smith AG, Osmond C, Oscier DG, Hamblin TJ. Treatment of acute myeloid leukemia in the elderly: a clinical dilemma. Hematol Oncol 1989; 7: 53-59.
62. Head DR, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams WL, Hewlett J, Willman C, Appelbaum FR. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86: 1717-1728.
63. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84: 111a.
64. Head DR, Downing JR. Pathology and immunology of leukemia. Curr Opin Oncol 1992; 4: 14-23.
65. Fialkow PJ, Singer JW, Adamson JW, Berkow RL, Friedman JM, Jacobson RJ, Moohr JW. Acute nonlymphocytic leukemia, expression in cells restricted to granulocytic and monocytic differentiation. New Engl J Med 1979; 301: 1-5.
66. Fialkow PJ, Singer JW, Adamson JW, Vaidya K, Dow LW, Ochs I, Moohr JW. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 1981; 57: 1068-1073.
67. Ferraris AM, Broccia G, Meloni T, Canepa L, Sessarego M, Gaetani GF. Clonal origin of cells restricted to moncytic differentiation in acute nonlymphocytic leukemia. Blood 1984; 64: 817-820.
68. Lo Coco F, Pelicci PG, D'Adamo F, Diverio D, Alimena G, Montefusco E, Arcese W, Avvisati G, De Felice L, Meloni G, Nervi C, Mandelli F, Saglio G. Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangements. Blood 1993; 82: 606-612.
69. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Grignani F, Pelicci PG. Structure and origin of acute promyelocytic leukemia myl/RAR-α and characterization of its retinoid-binding and transactivation properties. Oncogene 1991; 6: 1285-1292.
70. Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N, Gale RP, Lange B, Crist WM, Nowell PC, Croce CM, Canaani E. Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acacl Sci USA 1993; 90: 4631-4635.
71. Chen Z, Brand NJ, Chen A, Chen S-J, Tong J-H, Wang Z-Y, Waxman S, Zelent A. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J 1993; 12: 1161-1167.
72. Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. Fusion between transcription factor CBFB/PEBP2B and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-1044.
73. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 1991; 88: 10431-10434.
74. Morishita K, Parganas E, Willman CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Ihle JN. Activation of EVM gene expression in human acute leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937-3941.
75. Lampert F, Harhott J, Ritterbach J. Cytogenetic findings in acute leukaemias in infants. Br J Cancer 1992; 66: (Suppl XVIII) S20.
76. Cantu-Rajnoldi A, Biondi A, Jankovic M, Masera G, Rovelli A, Uderzo C, Head D, Raimondi S, Creutzig U, Ritter J, Mirro J. Diagnosis and incidence of acute promyelocytic leukemia (FAB M3 and M3 variant) in childhood. Blood 1993; 81: 2209-2210.
77. Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J, Kalwinsky DK, Dahl GV, Murphy SB, Crist WM, Williams DL. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. New Engl J Med 1989; 321: 136-142.
78. Sandoval C, Pui C-H, Bowman L, Heaton D, Hurwitz CA, Raimondi SC, Behm FG, Head DR. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993; 11: 1039-1045.